The availability of hepatitis B immune globulin (HBIG) and several oral antiviral therapies has reduced but not eliminated hepatitis B virus (HBV) recurrence. We aimed to determine the rate of HBV recurrence after orthotopic liver transplantation (OLT) in relation to virologic breakthrough pre-OLT and HBIG regimens post-OLT. Data from the NIH HBV-OLT database were analyzed. A total of 183 patients transplanted between 2001 and 2007 followed for a median of 42 months (range 1-81) post-OLT were studied. At transplant, 29% were hepatitis B e antigen (HBeAg) (+), 38.5% had HBV DNA > 5 log 10 copies/mL, 74% were receiving antiviral therapy. Twenty-five patients experienced virologic breakthrough before OLT. Post-OLT, 26%, 22%, 40% and 12% of patients received intravenous (IV) high-dose, IV low-dose, intramuscular low-dose and a finite duration of HBIG, respectively as maintenance prophylaxis. All but two patients also received antiviral therapy. Cumulative rates of HBV recurrence at 1 and 5 years were 3% and 9%, respectively. Multivariate analysis showed that listing HBeAg status and HBV DNA level at OLT were the only factors associated with HBV recurrence. In conclusion, low rates of HBV recurrence can be accomplished with all the HBIG regimens used when combined with antiviral therapy including patients with breakthrough pre-OLT as long as rescue therapy is administered pre-and post-OLT.
Introduction

The introduction of high-dose intravenous (IV) hepatitis B immune globulin (HBIG) monotherapy reduced the 3-year hepatitis B virus (HBV) recurrence rate after orthotopic liver transplantation (OLT) from 80% to 36% (1). However, HBIG monotherapy has limited efficacy in patients with high levels of HBV replication pretransplant, is very expensive, and may select for immune escape mutants (2-4). In the study by Samuel et al., the overall 3-year HBV recurrence rate among hepatitis B e antigen (HBeAg) and HBV DNA positive patients transplanted for cirrhosis was 83% (1). McGory et al. (5) and
observed that the half-life of HBIG was shorter in patients who were HBeAg positive or had detectable serum HBV DNA at the time of transplantation highlighting the importance of suppressing HBV replication prior to OLT. (10) (11) (12) (13) . However, several studies have reported that patients with antiviral resistance prior to OLT can be safely transplanted provided that rescue therapy is administered (14) (15) (16) . (17) (18) (19) (20) but the duration of posttransplant follow-up was short (1-3 years) 
Addition of oral antiviral agents to HBIG has resulted in a further decrease in HBV recurrence rates to <10% (7-9). Long-term administration of nucleos(t)ide analogs is associated with an increasing risk of antiviral drug resistance prior to OLT
With the availability of multiple nucleos(t)ide analogs, an important question is how much HBIG is needed to prevent HBV recurrence, when used in combination with antiviral therapy. Many investigators have explored low-dose HBIG regimens or HBIG withdrawal
Materials and Methods
Patient population
The NIH HBV-OLT study enrolled hepatitis B surface antigen (HBsAg) positive patients who were 13 years of age or older from 15 centers in the United States (21). The study was approved by the Institutional Review Board representing each of the participating centers, and written informed consent was obtained from all patients prior to study entry.
Results
Characteristics of patients
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